NewsEvents

Your Yourlocation: Home > Tiotropium bromide(136310-93-5) can significantly reduce the incidence of acute exacerbation of asthma

Tiotropium bromide(136310-93-5) can significantly reduce the incidence of acute exacerbation of asthma.

Tiotropium bromide(136310-93-5) also significantly improved lung function in asthmatic patients who remained symptomatic after ICS / LABA therapy.

"The results of these trials exceeded our expectations, although we expected that the addition of tiotropium bromide(136310-93-5) to conventional therapy would improve the quality of the treatment," said lead author Huib AMKerstjens of the University of Groningen Medical Center in the Netherlands. "We have also observed a significant reduction in the risk of acute exacerbations, and it is particularly noteworthy that all patients had previously undergone optimal maintenance therapy recommended by the GINA guidelines. "

The PrimoTinA-asthma ™ trial consisted of two double-blind, parallel-group trials in which asthmatic patients were treated with at least a high dose of ICS / LABA, and the FEV1 [c] percentage of predicted bronchodilator therapy was <80% , While the asthma control questionnaire score ≥ 1.5. A total of 912 patients were randomized to a 48-week addition of tiotropium bromide(136310-93-5) Respimat 5ug or placebo.

Address: TEL:0531-82375879 Tiotropium Bromide
© Copyright(C)2014 JINAN DEXINJIA BIO & TECH CO., LTD All Rights Reserved